Nazca Capital reinforces Phibo and signs a former Gamesa to drive its expansion

The company, led by the former general manager of Futbol Club Barcelona, has incorporated Javier Lasunción into its team. Phibo was strengthened last September with the purchase of Sineldent.

Phibo is a leading Spanish multinational company in implantology, CAD-CAM prostheses, digital solutions, and services. Phibo has been researching, developing, manufacturing, and marketing dental solutions for over 25 years with a strong research focus and a high scientific component.

Discover quality content across all passions and interests. Personalized financial headlines, biotech, crowdfunding, and more. The Born2Invest mobile app will make you feel like you have spent your time well.

Phibo shakes up operations

The Spanish dental company, controlled by Nazca Capital, has hired Javier Lasunción, formerly of Gamesa, to lead its operations department. The executive will report to Ignacio Mestre, the group’s CEO, and former Barça manager, and will be in charge of the company’s expansion in Spain and Latin America.

Lasuncion is an industrial engineer from the University of Navarra, PDD from Iese, and has completed a program in Business Administration from Insead. Previously, he worked as operations manager for the European market for Vestas, a company specialized in the sustainable energy sector.

After his time at Vestas, Lasunción worked at Gamesa as sales operations manager for Europe, the Middle East, and Africa. From there, he jumped to Came Parkare, as a business unit manager, to later become the operations manager of Macsa, a Catalan company specialized in the design and distribution of coding and marking lasers.

Phibo has nearly 300 employees and a turnover of more than $33 million

Phibo is an integrated dental solutions company that was founded in 1986 under the name Implandent by brothers Juan Carlos, Miguel, and Francisco Javier García Sabán. In 2011 it was transformed into Phibo and began an internationalization plan. The company, specialized in implantology solutions, CAD/CAM prosthesis manufacturing, and digitalization solutions, has a technology center of more than 8,000 square meters in Barcelona dedicated to R&D, industrial production and training.

Phibo has almost 300 employees, a turnover of more than $35 million (€32 million), and operates in around twenty markets, mainly Spain, Italy, Portugal, Turkey, Chile, and Colombia, where it has a production plant in Bogotá. Since 2018, the venture capital fund Nazca Capital has held the majority of the company’s capital, with a 55% stake. The García Sabán brothers hold a percentage of over 40%.

Nazca Capital simultaneously manages the Nazca IV Fund of $295 million (€275 million) and the Nazca V Fund of $162 million (€150 million) to invest in smaller SMEs, both funds committed mainly by international institutional investors. The management company has a portfolio of eleven companies (in addition to Phibo): OM Group (visual communication), Gestair (aviation), FoodBox (catering), Diater (biopharmaceuticals), and Cinelux (lighting for cinema and television), among others.

Last September, Phibo announced the acquisition of Sineldent, a Galician company specialized in dental prosthesis. The two companies have a combined turnover of nearly $43 million (€40 million), more than 320 employees and four production plants in Sentmenat (Barcelona), Ourense, Madrid, and Bogotá (Colombia). The joint annual production volume exceeds one million units.

__

(Featured image by Peter Kasprzyk via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce., a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.